factsheet_company_2012_04web

First Page		Document Content
Date: 2012-09-24 10:16:16 Glycoproteins Medicine Biotechnology Monoclonal antibodies Monoclonal antibody therapy Antibody Polyclonal antibodies Immunoglobulin G Symphogen Biology Immunology Immune system		factsheet_company_2012_04web Add to Reading List Source URL: www.merus.nl Download Document from Source Website File Size: 1,13 MB Share Document on Facebook

	January 8, 2016 BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum. 1. Baxalta, Symphogen Ink $1.6 Billion ImmunoOncology Deal In yet DocID: 1rlhw - View Document
	Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology  Partnership aims to advance development of novel immune checkpoint DocID: 1mqfS - View Document
	Symphogen Enters into strategic collaboration with Genentech for antibody therapeutics SYMPHOGEN ENTERS INTO STRATEGIC COLLABORATION WITH GENENTECH FOR ANTIBODY THERAPEUTICS IN INFECTIOUS DISEASE COPENHAGEN, Denmark – DocID: 1aQYq - View Document
	PDF Document DocID: 17pgY - View Document
	FOR IMMEDIATE RELEASE Theraclone Sciences’ I-‐STAR™ Technology Chosen by Wellcome Trust to Identify Therapeutic Antibodies Against Ebol DocID: 178Az - View Document